Search
GTS-21
go.drugbank.com/drugs/DB05708InvestigationalGTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athe...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesGPI-1485
go.drugbank.com/drugs/DB05814InvestigationalGPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without a...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSeletracetam
go.drugbank.com/drugs/DB05885InvestigationalSeletracetam is a pyrrolidone derivative and with a structural similarity to newer generation antiepileptic drug levetiracetam. It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppressio...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDovitinib
go.drugbank.com/drugs/DB05928InvestigationalDovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersCariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigationalCariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT1A receptors and as an antagonist at ser...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigationalTirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsNoscapine
go.drugbank.com/drugs/DB06174ApprovedCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP3A InhibitorsRomidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesZosuquidar
go.drugbank.com/drugs/DB06191InvestigationalIts action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Categories: P-glycoprotein inhibitorsRufinamide
go.drugbank.com/drugs/DB06201ApprovedRufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers